A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

October 26, 2027

Study Completion Date

October 25, 2029

Conditions
Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
DRUG

HDM2005

HDM2005 will be administered as an intravenous injection.

DRUG

Rituximab or Rituximab biosimilar

Rituximab or Rituximab biosimilar will be administered as an intravenous injection.

DRUG

Gemcitabine

Gemcitabine will be administered as an intravenous injection.

DRUG

Oxaliplatin

Oxaliplatin will be administered as an intravenous injection.

DRUG

Cyclophosphamide

Cyclophosphamide will be administered as an intravenous injection.

DRUG

Doxorubicin

Doxorubicin will be administered as an intravenous injection.

DRUG

Prednisone

Prednisone will be administered orally.

Trial Locations (21)

100142

RECRUITING

Peking University Cancer Hospital, Beijing

110004

NOT_YET_RECRUITING

Shengjing Hospital Affiliated to China Medical University, Shenyang

130021

NOT_YET_RECRUITING

The first hospital of Jilin University, Changchun

150081

NOT_YET_RECRUITING

Affiliated Tumor Hospital of Harbin Medical University, Harbin

215005

NOT_YET_RECRUITING

Second Affiliated Hospital of Soochow University, Suzhou

250117

NOT_YET_RECRUITING

Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital), Jinan

310003

NOT_YET_RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

330000

NOT_YET_RECRUITING

The First Affiliated Hospital Of Nanchang University, Nanchang

350000

NOT_YET_RECRUITING

Fujian Cancer Hospital, Fuzhou

410023

NOT_YET_RECRUITING

HunanCancer Hospital, Changsha

430022

NOT_YET_RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

430030

NOT_YET_RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

450000

NOT_YET_RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

450008

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

510050

NOT_YET_RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

530021

NOT_YET_RECRUITING

The Affiliated Tumor Hospital of Guangxi Medical University, Nanning

610041

NOT_YET_RECRUITING

West China Hospital,Sichuan University, Chengdu

650033

ACTIVE_NOT_RECRUITING

The Second Affiliated Hospital of Kunming Medical UniversityThe Second Affiliated Hospital of Kunming Medical University, Kunming

650118

NOT_YET_RECRUITING

Yunnan Cancer Hospital, Kunming

710061

NOT_YET_RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

030013

NOT_YET_RECRUITING

Shanxi Cancer Hospital, Taiyuan

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY

NCT07124936 - A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter